Clinical Trial Update: Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating bortezomib with carboplatin in metastatic pancreatic cancer was terminated; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Bortezomib (bortezomib)
• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 2 | Status: TERMINATED | Results posted: 2011-07-15